AIM
ALT icon

Aigen Investment Management’s Altimmune ALT Stock Holding History

Aigen Investment Management’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-11,712
Closed -$41.3K – 804
2023
Q2 		$41.3K Buy
+11,712
New +$52.6K 0.01% 706

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Aigen Investment Management's ALT Position: Q3 2023 in Review

Aigen Investment Management sold out of Altimmune (ALT) in Q3 2023, closing a stake of 11,712 shares — an estimated $41.3K sold.

Aigen Investment Management first reported a position in ALT in Q2 2023 and held it in 1 quarter. The position peaked at $41.3K in Q2 2023. 112 funds tracked by Wall St. Rank hold ALT as of Q3 2023.

  • Aigen Investment Management reported no remaining Altimmune position as of Q3 2023 after selling out during the quarter.
  • Aigen Investment Management sold 11,712 Altimmune shares in Q3 2023, an estimated $41.3K.
  • Aigen Investment Management first reported a position in Altimmune in Q2 2023 and held it in 1 quarter.
  • Aigen Investment Management's Altimmune position peaked at $41.3K in Q2 2023.
  • 112 funds tracked by Wall St. Rank held Altimmune as of Q3 2023.

Based on Aigen Investment Management's 13F filing for Q3 2023, filed 13 Nov 2023.